| European Case Law Identifier: | ECLI:EP:BA:2018:T087213.20180828 | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Date of decision: | 28 August 2018 | ||||||||
| Case number: | T 0872/13 | ||||||||
| Application number: | 05766825.3 | ||||||||
| IPC class: | C12P 21/00 C07K 14/745 C12N 9/64 |
||||||||
| Language of proceedings: | EN | ||||||||
| Distribution: | D | ||||||||
| Download and more information: |
|
||||||||
| Title of application: | O-LINKED GLYCOFORMS OF FACTOR VII AND METHOD TO MANUFACTURE THEM | ||||||||
| Applicant name: | Novo Nordisk Health Care AG | ||||||||
| Opponent name: | Strawman Limited | ||||||||
| Board: | 3.3.01 | ||||||||
| Headnote: | - | ||||||||
| Relevant legal provisions: |
|
||||||||
| Keywords: | Oral proceedings - held in absence of appellant Acceleration of proceedings - (no) Late-filed evidence - submitted with the statement of grounds of appeal or reply thereto: admitted Late-filed evidence - submitted at a late stage of appeal proceedings and complex: not admitted Novelty - implicit disclosure (yes/no) Amendments - allowable (yes) Claims - clarity after amendment (yes) Sufficiency of disclosure - (yes) Inventive step - (yes) |
||||||||
| Catchwords: |
- |
||||||||
| Cited decisions: |
|
||||||||
| Citing decisions: |
|
||||||||
Source: http://www.epo.org/law-practice/case-law-appeals/recent/t130872eu1.html
Date retrieved: 17 May 2021